Abstract

Although aromatic anticonvulsants are usually well tolerated, they can cause cutaneous adverse drug reactions in up to 10% of patients. The clinical manifestations of the antiepileptics-induced hypersensitivity reactions (AHR) vary from mild skin rashes to severe cutaneous drug adverse reactions which are related to high mortality and significant morbidity. Genetic polymorphisms in cytochrome P450 genes are associated with altered enzymatic activity and may contribute to the risk of AHR. Here we present a case-control study in which we genotyped SNPs of CYP2C19, 2C9 and 3A5 of 55 individuals with varying severities of AHR, 83 tolerant, and 366 healthy control subjects from São Paulo, Brazil. Clinical characterization was based on standardized scoring systems and drug patch test. All in vivo investigation followed the ENDA (European Network of Drug Allergy) recommendations. Genotype was determined by real time PCR using peripheral blood DNA as a template. Of all 504 subjects, 65% were females, 45% self-identified as Afro-American, 38% as Caucasian and 17% as having non-African mixed ascendancy. Amongst 55 subjects with AHR, 44 had severe cutaneous drug adverse reactions. Of the 46 drug patch tests performed, 29 (63%) were positive. We found a strong association between the absence of CYP3A5*3 and tolerant subjects when compared to AHR (p = 0.0002, OR = 5.28 [CI95% 2.09–14.84]). None of our groups presented positive association with CYP2C19 and 2C9 polymorphisms, however, both SNPs contributed to separation of cases and tolerants in a Classification and Regression Tree. Our findings indicate that drug metabolism genes can contribute in the tolerability of antiepileptics. CYP3A5*3 is the most prevalent CYP3A5 allele associated with reduced enzymatic function. The current study provides evidence that normal CYP3A5 activity might be a protective factor to aromatic antiepileptics-induced hypersensitivity reactions in Brazilian subjects.

Highlights

  • Aromatic anticonvulsants (ARA) are important drugs effective in the treatment of epilepsy, trigeminal neuralgia, and bipolar disorder [1,2]

  • The CYP3A5Ã3/Ã3 genotype was associated with increased half-life of CBZ in African-Americans, but no significant association was observed in Caucasians [18,19]

  • This study is the first and most broad case-control study ever conducted towards the association of CYP alleles and aromatic antiepileptics-induced hypersensitivity reactions in Brazilian subjects

Read more

Summary

Introduction

Aromatic anticonvulsants (ARA) are important drugs effective in the treatment of epilepsy, trigeminal neuralgia, and bipolar disorder [1,2]. The clinical manifestations of the antiepileptics-induced hypersensitivity reactions (AHR) vary from mild skin rashes to severe cutaneous drug adverse reactions (SCARs), such as Stevens—Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) [3]. These SCARs are related to high mortality and significant morbidity. Several Single Nucleotide Polymorphisms (SNPs) have major consequences in the expression and activity of these enzymes, the results are still not comparable in different populations worldwide [16,17,18] These informations are relevant for pharmacogenetics strategies, in which the knowledge of CYP genotype may lead to individualized drug dosing and improved therapeutics

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call